Differences in COVID-19 Vaccine Response by Sex in HIV-Infected Individuals Stem from Imbalance in Complement C3a Activation

Background
Identifying individual differences in immune responses following vaccination is a key challenge in establishing precision vaccine strategies for infectious diseases. During the SARS-CoV-2 pandemic, large-scale vaccinations were administered worldwide; however, distinct immune response patterns were consistently observed in populations with underlying conditions or among immunocompromised individuals. In particular, individuals with Human Immunodeficiency Virus (HIV-1) infection are classified as a high-risk group vulnerable to pathogen infections and inadequate responses to vaccine stimulation due to chronic immune activation and immune system damage.
The complement system, which acts as a bridge between innate and adaptive immunity, is a crucial factor in determining not only early defense during infection but also the intensity of vaccine-induced antibody responses. Anaphylatoxin protein fragments produced during the complement activation process stimulate antigen-presenting cells and amplify B-cell responses, aiding the formation of humoral immunity. To date, COVID-19 vaccination studies have mostly focused on measuring neutralizing antibody titers or T-cell responses, and there has been insufficient systematic analysis regarding how biological sex differences within immunocompromised groups affect complement system regulatory pathways. This has raised the need to systematically identify how immune response trajectories may differ between men and women even under the same infection status.
Key Findings
Researchers constructed a cohort of men aged 36 to 86 and women aged 39 to 83 to track immune responses before and after vaccination. The analysis cohort was stratified into four groups: men with HIV-1 (MWH), uninfected men (MWOH), women with HIV-1 (WWH), and uninfected women (WWOH). The evaluation results showed that the post-vaccination antibody response levels in the HIV-1-infected female group were significantly lower than those in the HIV-1-infected male group.
A notable point was the change in complement component 3a (C3a) levels, a key indicator of complement activation. In the infected male group, blood C3a levels increased significantly after vaccination, whereas almost no change was observed in the infected female group. This indicates that the release of early products of the complement cascade was not properly induced in infected females.
To elucidate the molecular mechanisms underlying this difference in complement activation, the researchers precisely measured the levels of C5, C5a, C1 esterase inhibitor (C1-INH), factor H, and the binding capacity of circulating immune complex-C1q (CIC-C1q). Multi-faceted comparative analysis confirmed that the C3 convertase activation observed in the infected male group was primarily driven by C1-INH levels and anti-spike (anti-S) antibody titers.
A different pattern was observed during the formation of the terminal complement complex, a downstream pathway. No statistically significant differences in C5 and C5a concentrations were found in any group before and after vaccination. This supports the finding that the complement response triggered by vaccine stimulation is selectively controlled at the early C3 convertase level, rather than being indiscriminately expanded to the C5 convertase stage, which causes excessive tissue inflammation.
Significance and Outlook
This study holds high academic value as it empirically demonstrates that biological sex is a key variable determining the magnitude and quality of vaccine-induced immune responses in chronic viral infection states. Previously, sex-based immune differences were often examined at a macroscopic level in terms of sex hormone levels or the expression of sex chromosome-linked genes. This analysis elucidated the molecular imbalance in the immune response by specifically identifying the differences between C1-INH, a complement cascade regulatory protein, and the C3 convertase activation pathway.
From a clinical perspective, it suggests the need for a precise redesign of vaccination strategies for the HIV-1-infected female patient group. This is because there is a risk that standard doses may result in insufficient antibody formation and complement stimulation. Subsequent research will focus on adjusting vaccination intervals or selectively applying adjuvant formulations to support complement system activation.
As this is a single-cohort study, additional verification is required regarding the subtle effects that clinical variables, such as history of antiretroviral therapy (ART) use and duration of viral suppression, may have had on the complement system. If long-term follow-up data for individual patients are supplemented, it is expected to contribute to the development of customized infectious disease defense systems for high-risk immunocompromised cohorts.
Regulation of complement activity influences immunity and clinical outcomes of SARS-CoV-2 infections. Here we investigated antibody responses to SARS-CoV-2 vaccination and complement activity in men (age 36 to 86) and women (age 39 to 83) with (MWH, WWH) and without (MWOH, WWOH) HIV-1. Antibody responses in WWH were lower than in MWH. WWH also had negligible change in blood C3a post-immunization, whereas MWH had greater C3a levels. We investigated the levels of C5, C5a, and C1-INH, as well as factor H and circulating immune complex-C1q (CIC-C1q) binding, to understand the regulation of complement activity. We found that C1-INH and anti-S antibody levels were driving the differences in C3 convertase activity in MWH. No significant differences were found between C5 and C5a in both cohorts, suggesting that C5 convertase is not being activated. These results show that biological sex may impact SARS-CoV-2 immune responses and highlight the need for further investigation.
These analysis results clearly demonstrate the need for clinical differentiation in vaccination protocols for immunocompromised patients. Currently, in clinical practice, HIV-infected individuals are grouped as a single immunocompromised population and recommended to receive infectious disease vaccines at the same intervals and dosages. However, the deficiency in C3a activation and lower antibody titers observed in HIV-infected women raise questions about the effectiveness of the existing uniform vaccination approach. In clinical practice, biomarker monitoring of anti-spike antibody titers and complement byproducts after vaccination can be implemented to identify patient groups with vulnerable responses. From the perspective of the vaccine pharmaceutical industry, research areas could expand to include the development of targeted formulations that reflect sex-specific immune characteristics, such as novel adjuvant combinations that directly stimulate innate immune receptors to enhance C3 convertase activity or high-dose antigen regimens.